NuCana Shares Results For Cancer Therapy, Sees Partial Responses In Phase 1b/2 Study
NuCana Shares Results For Cancer Therapy, Sees Partial Responses In Phase 1b/2 Study
nucana分享了癌症治療的結果，在1b/2研究中看到了部分反應
NuCana plc (NASDAQ: NCNA) announced that initial data from the ongoing Phase 1b/2 modular study (NuTide:303) investigating NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid
nucana plc（納斯達克:NCNA）宣佈，正在進行的第1b/2模塊研究（NuTide:303）探究NUC-3373與PD-1抑制劑帕博利珠單抗聯合治療晚期固體腫瘤的初步數據
NuCana plc (NASDAQ:NCNA) announced that initial data from the ongoing Phase 1b/2 modular study (NuTide:303) investigating NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors (Module 1) and in combination with docetaxel for patients with lung cancer (Module 2) have been published in MedRxiv, the preprint server for Health Sciences.
nucana plc（納斯達克:NCNA）宣佈，正在進行的第1b/2模塊研究（NuTide:303）探究NUC-3373與PD-1抑制劑帕博利珠單抗聯合治療晚期固體腫瘤（第1模塊），以及與紫杉醇聯合治療肺癌患者（第2模塊）的初步數據已經在健康科學的預印本服MedRxiv上發表
Module 1 included 12 patients with a variety of solid tumors who had exhausted all other treatment options. The majority...
第1模塊包括12名患有各種固體腫瘤且...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間